Rationale: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP.
Idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial pneumonia characterized by worsening dyspnea and progressive loss of lung function (1) . According to the American Thoracic Society/European Respiratory Society/ Japanese Respiratory Society/Latin American Thoracic Association diagnostic guidelines published in 2011, diagnosis of IPF requires the exclusion of other known causes of interstitial lung disease and the presence of the usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) in patients not subjected to a surgical lung biopsy (1) . The UIP pattern includes subpleural basal predominance, reticular abnormality, honeycombing, and the absence of features inconsistent with UIP. For patients with a possible UIP pattern (i.e., reticulation with subpleural and basal predominance and absence of features inconsistent with UIP, but no honeycombing) or features inconsistent with UIP on HRCT, the guidelines state that a surgical lung biopsy is required to make a definitive diagnosis (1) . The accuracy of a diagnosis of IPF increases with multidisciplinary discussion among clinicians, radiologists, and pathologists, particularly in cases in which the radiologic and histopathologic patterns are discordant (2, 3) . However, because obtaining a surgical lung biopsy is not without risk for patients with severe physiologic impairment or substantial comorbidity, the risks of a surgical lung biopsy may outweigh the benefits of establishing a secure diagnosis of IPF (1, 4, 5) .
Because the clinical course and response to treatment of patients who do not meet the current diagnostic criteria for IPF are unknown, investigating the behavior of disease across diagnostic subgroups is of great relevance (6) . Furthermore, differences in diagnostic criteria required for participation in clinical trials in IPF may lead to different patient populations being assessed in different trials (7) .
Nintedanib is an intracellular inhibitor of tyrosine kinases (8) that has been approved for the treatment of IPF in several countries and regions, including the United States (9), Europe (10) , and Japan, and it has received a conditional recommendation for use in the latest international clinical practice guideline for the treatment of IPF (11) . The two replicate, randomized, placebo-controlled phase III INPULSIS trials investigated the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF (12) . To enter the INPULSIS trials, patients had to have a diagnosis of IPF established <5 years before randomization and an HRCT scan performed within 12 months of randomization. In the absence of a surgical lung biopsy, patients had to have honeycombing and/or a combination of traction bronchiectasis and reticulation in the absence of atypical features of UIP on HRCT to be eligible to participate (12) .
In both INPULSIS trials, nintedanib reduced the annual rate of decline in FVC by approximately 50% compared with placebo (primary endpoint) (12) . For the two key secondary endpoints, time to first investigator-reported acute exacerbation and change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over 52 weeks, a significant benefit of nintedanib versus placebo was observed in INPULSIS-2 but not in INPULSIS-1 (12) . Adverse events were manageable for most patients; diarrhea was the most frequent adverse event in patients treated with nintedanib (12) .
In this analysis, we investigated the potential impact of diagnostic subgroups on the effect of nintedanib in patients with IPF using pooled data from the INPULSIS trials. Some of these results have been reported in an abstract (13) .
Methods
To qualify to enter the INPULSIS trials in the absence of a surgical lung biopsy, HRCT criteria A and B and C, or A and C, or B and C had to be met, where criterion A was definite honeycomb lung destruction with basal and peripheral predominance, criterion B was the presence of reticular abnormality and traction bronchiectasis consistent with fibrosis with basal and peripheral predominance, and criterion C was the absence of atypical features, specifically nodules and consolidation, with ground glass opacity, if present, being less extensive than a reticular opacity pattern. HRCT scans exemplifying patterns A and B and C, and B and C are shown in Figures 1A and 1B. All HRCT scans were assessed by one expert radiologist (D.M.H.). Surgical lung biopsies, if available, were reviewed by one expert pathologist (A.G.N.) and used to confirm eligibility. In cases in which there was disagreement between the radiologist and pathologist about whether a patient should be included in the trial, they discussed the case, and a consensus was reached.
Post hoc subgroup analyses of patients with honeycombing on HRCT and/or confirmation of UIP by surgical lung biopsy versus patients with features of possible UIP and traction bronchiectasis on HRCT (criteria B and C) and no surgical lung biopsy were conducted using pooled data from the two INPULSIS trials. Baseline characteristics were summarized by subgroup to determine whether there were any confounding factors. Analyses were conducted on the primary and key secondary endpoints by repeating the primary analysis of each endpoint within each subgroup. The annual rate of decline in FVC was analyzed based on random coefficient regression with fixed effects for trial, treatment, sex, age, height, and random effects for patient-specific intercept and time. Time to first investigator-reported acute exacerbation was analyzed based on a Cox's regression model with terms for trial, treatment, sex, age, and height. The change from baseline in SGRQ over 52 weeks was analyzed based on a mixed model for repeated measures, with fixed effects for trial, treatment, visit, treatment-by-visit, baseline SGRQ total score, baseline SGRQ total score-by-visit, and random effect for the patient. To test if there was a different effect of nintedanib between the subgroups, an interaction P value was calculated. For the primary endpoint, the terms subgroup and an interaction term treatment-by-time-by-subgroup were included in the model. For the key secondary endpoints, the terms subgroup and interaction term treatment-by-subgroup were included in the model.
To check the robustness of the subgroup analyses, we also assessed the absolute change from baseline in FVC percent predicted over 52 weeks and the time to absolute decline in FVC >5% or >10% predicted, or death, over 52 weeks in each subgroup using the same approach as for the other endpoints to calculate the interaction P values. The absolute change from baseline in FVC percent predicted over 52 weeks was analyzed using a mixed model for repeated measures, with fixed effects for trial, treatment, visit, sex, age, height, treatment-by-visit, baseline FVC percent predicted, baseline FVC percent predicted-by-visit, and a random effect for the patient. The time to absolute decline in FVC >5% or 10% predicted, or death over 52 weeks was analyzed using a Cox's regression model, with terms for trial, treatment, sex, age, and height. Analyses were based on data collected up to 372 days after randomization (52 wk plus 7 d margin). SAS version 9.2 or later (SAS Institute, Cary, NC) was used to perform the analyses. Safety was assessed via clinical and laboratory evaluation, and the recording of adverse events with onset after the first dose and up to 28 days after the last dose of the study drug in patients who received >1 dose of the study drug. Safety analyses were repeated by subgroup and were descriptive.
Results

Patients
All the patients in the INPULSIS trials had a diagnosis of IPF established in clinical practice <5 years before randomization. Central review of HRCT scans of the 1061 patients treated in the trials showed that 567 (53.4%) of the patients had definite honeycomb lung destruction with basal and peripheral predominance (criteria A, B, and C, or criteria A and C), whereas in 468 (44.1%) of the patients, honeycombing was absent on HRCT but criteria B and C were met ( (Table 1 ). There were no major differences in demographic and disease characteristics between the subgroups, and baseline characteristics were similar between the nintedanib and placebo groups within each subgroup, indicating that assessment of the effect of nintedanib across subgroups would not be affected by confounding factors ( Table 2 ). In the subgroup of patients with honeycombing and/or biopsy, there were higher proportions of Asian patients (34.6 vs. 21.3%), patients with centrilobular emphysema (44.8 vs. 28.4%), and former or current smokers (75.8 vs. 64.2%) than in the subgroup of patients without honeycombing or biopsy. 425   213  210  209  206  205  205  204  204  202  195  190  189  185 171   298  295  293  287  286  283  276  274  271  267  262  258  252 237   125  124  122  121  121  120  117  115  115  114  114  109  107 104   422  418  403  400  390  385  380  378  375  372  364 352 321 Figure 4 . Time to first acute exacerbation over 52 weeks by subgroup. SLB = surgical lung biopsy; UIP = usual interstitial pneumonia.
ORIGINAL ARTICLE Annual Rate of Decline in FVC
The adjusted annual rate of decline in FVC was consistent between placebo-treated patients with honeycombing and/or biopsy and without honeycombing or biopsy (2225.7 and 2221.0 ml/yr, respectively).
In the overall pooled population, nintedanib significantly reduced the annual rate of decline in FVC compared with placebo (difference of 109.9 ml/yr; 95% confidence interval [CI], 75.9-144.0; P , 0.0001) (12) . In patients with honeycombing and/or biopsy, the adjusted annual rate of decline in FVC was 2108.7 ml/yr in the nintedanib group (difference vs. placebo of 117.0 ml/yr; 95% CI, 76.3-157.8) (Figure 2) . In patients without honeycombing or biopsy, the adjusted annual rate of decline in FVC was 2122.0 ml/yr in the nintedanib group (difference vs. placebo of 98.9 ml/yr; 95% CI, 36.4-161.5) (Figure 2 ). The treatment-by-subgroup interaction P value was not significant (P = 0.8139), indicating that the treatment effect of nintedanib was not different between the subgroups. The treatment effect in both subgroups was also consistent with the treatment effect in the overall pooled population.
The primary endpoint results were supported by the observed changes from baseline in FVC over time in each subgroup ( Figure 3) . Importantly, the curves for change from baseline in FVC over time in the placebo groups were similar between the subgroups, indicating a similar rate of decline in FVC, irrespective of the diagnostic criteria. The results for the additional lung function outcomes were consistent across the subgroups and are presented in Table 3 .
Investigator-reported Acute Exacerbations
The proportion of patients with >1 acute exacerbation was low in placebo-treated patients in both subgroups, but was consistent between patients without honeycombing or biopsy and patients with honeycombing and/or biopsy (9.6% [12 patients] vs. 6.7% [20 patients], respectively) ( Figure 4) . The proportion of nintedanib-treated patients with >1 acute exacerbation was 4.7% (10 patients) and 4.9% (21 patients) in these subgroups, respectively (Figure 4) .
In the overall pooled population, there was a numerical but not statistically significant reduction in the risk of having a first acute exacerbation in favor of nintedanib (hazard ratio [HR], 0.64; 95% CI, 0.39-1.05; P = 0.0823) (12) . In patients with honeycombing and/or biopsy, the HR for time to first acute exacerbation was 0.75 (95% CI, 0.40-1.38) in favor of nintedanib (Figure 4) . In patients without honeycombing or biopsy, the HR for time to first acute exacerbation was 0.50 (95% CI, 0.22-1.17) in favor of nintedanib (Figure 4) . The treatment-by-subgroup interaction P value was not significant (P = 0.3747), indicating that the treatment effect of nintedanib was not different between the diagnostic subgroups. The treatment effect in both subgroups was also consistent with the treatment effect in the overall pooled population.
SGRQ Total Score
Among placebo-treated patients, the adjusted mean change from baseline in SGRQ total score at week 52 was similar in patients with honeycombing and/or biopsy than in patients without honeycombing or biopsy (5.50 vs. 3.80) ( Figure 5 ). The adjusted mean change from baseline in SGRQ total score at week 52 was 4.46 and 1.93 for nintedanib-treated patients in these subgroups, respectively ( Figure 5 ).
In the overall pooled population, there was no significant difference between nintedanib and placebo in the change from baseline in SGRQ total score at week 52 (between-group difference of 21.43 points; 95% CI, 23.09 to 0.23; P = 0.0923) (12) .
In patients with honeycombing and/or biopsy, the nintedanib versus placebo difference in the adjusted mean change from baseline in SGRQ total score at week 52 was 21.04 (95% CI, 23.02 to 0.95) ( Figure 5 ). In patients without honeycombing or biopsy, the nintedanib versus placebo difference in the adjusted mean change from baseline in SGRQ total score at week 52 was 21.87 (95% CI, 24.90 to 1.16) ( Figure 5 ). The treatmentby-subgroup interaction P value was not significant (P = 0.6680), which indicated that the treatment effect of nintedanib was not different between the diagnostic subgroups. The treatment effect in both subgroups was also consistent with the treatment effect in the overall pooled population.
Adverse Events
A summary of adverse events in each subgroup is presented in Table 4 . There were no major differences in the safety profile of nintedanib between the subgroups by diagnostic criteria. The proportions of patients who had >1 serious adverse event were comparable between the nintedanib and placebo groups within each subgroup and were consistent with the overall pooled population (12) . Also consistent with the results in the overall population, diarrhea was the most frequent adverse event in nintedanib-treated patients in both subgroups, reported in 64.0% of patients with honeycombing and/or biopsy and 59.2% of patients without honeycombing or biopsy, compared with 18.8 and 17.6% of placebo-treated patients in these subgroups, respectively. However, as observed for the overall population, only a small proportion of nintedanib-treated patients (4.5 and 4.2% in these subgroups, respectively) permanently discontinued the study medication due to diarrhea.
Discussion
All the patients who participated in the INPULSIS trials had been diagnosed with IPF in accordance with clinical practice, based on clinical assessment and reasoning, including consideration of HRCT data. We believe that a considerable number of patients who have possible UIP according to current diagnostic guidelines also have traction bronchiectasis, and that the subgroup of patients in our study who had a combination of traction bronchiectasis and reticulation on HRCT represent an important subgroup of the patients with IPF seen in clinical practice. In this post hoc analysis of data from 1061 patients treated in the INPULSIS trials, we have shown, for the first time, that the rate of decline in FVC in patients with possible UIP with traction bronchiectasis and no surgical lung biopsy is the same as in patients with a diagnosis of IPF according to current guidelines (i.e., with honeycombing on HRCT and/or confirmation of UIP on surgical biopsy) (1). The proportion of patients who had acute exacerbations was also consistent between these subgroups. Furthermore, we have demonstrated that there was no difference in the treatment effect of nintedanib on the rate of decline in FVC, acute exacerbations, or change in SGRQ score between these diagnostic subgroups. These are the first data to show the efficacy of a treatment for IPF in reducing FVC decline in patients with possible UIP with traction bronchiectasis. The adverse event profile of nintedanib in both subgroups was similar and as expected based on the adverse events reported in the overall patient population (12) . The presence of honeycombing on HRCT has been correlated with a lower FVC percent predicted and lower diffusing capacity of the lung for carbon monoxide (DL CO ) percent predicted in some but not all studies (1, 14, 15) . In our study, FVC percent predicted and DL CO percent predicted at baseline were similar in patients with honeycombing as in patients without honeycombing or biopsy.
Challenges exist to basing the diagnosis of IPF on the presence of honeycombing on HRCT or a surgical lung biopsy. Atypical HRCT patterns are common in patients with biopsy-proven UIP (16) . Not all patients with IPF have honeycombing on HRCT (17) . Data from the INSIGHTS-IPF (Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis) registry of patients with IPF in clinical practice in Germany found that of 447 patients with an HRCT scan, 23.7% had possible UIP (18) . In the INPULSIS trials, fewer than half of the patients had honeycombing on HRCT at baseline. Interobserver agreement for the identification and differentiation of honeycombing (e.g., vs. traction bronchiectasis) on HRCT is low and is complicated by the presence of emphysema, which may mimic honeycombing (7, 16, 17, (19) (20) (21) . Furthermore, in patients with IPF who have comorbidities, which are common in patients with IPF (22) , or in patients with severe physiologic impairment, surgical lung biopsy may pose a significant risk (4).
In conclusion, our findings show that patients diagnosed with IPF in accordance with clinical practice who have possible UIP with traction bronchiectasis on HRCT (confirmed by central review) have disease that progresses in a similar way and responds similarly to nintedanib, as do patients who have honeycombing on HRCT and/or confirmation of UIP by biopsy in accordance with current diagnostic guidelines. The striking similarity observed in the natural history of disease and the effect of nintedanib treatment between these subgroups supports the use 
